SCHEMBL5606900

SCHEMBL5606900

NOC(=O)CCc1ccc(O)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 2/20 0.50
ESR2 Q92731 1/20 0.50
TDP1 Q9NUW8 3/20 0.49
KMT2A Q03164 3/20 0.49
KDM4E B2RXH2 3/20 0.49
ALDH1A1 P00352 2/20 0.49
CYP2C19 P33261 2/20 0.49
CYP19A1 P11511 2/20 0.49
MEN1 O00255 2/20 0.49
HDAC2 Q92769 1/20 0.49
HDAC8 Q9BY41 1/20 0.49
SLC16A3 O15427 1/20 0.49
LMNA P02545 1/20 0.49
TTR P02766 1/20 0.49
TP53 P04637 1/20 0.49
CYP1A2 P05177 1/20 0.49
POLB P06746 1/20 0.49
CYP3A4 P08684 1/20 0.49
GAA P10253 1/20 0.49
CYP2D6 P10635 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL28087587 0.98 TDP1 (0.50) ESR1ESR2TDP1KMT2AKDM4E
SCHEMBL27611058 0.89 TRPV1 (0.47) ESR1ESR2TDP1KMT2AKDM4E
SCHEMBL3293098 0.83 ESR1 (0.54) ESR1ESR2TDP1KMT2AKDM4E
SCHEMBL14765512 0.82 CYP4F2 (0.51) TDP1KMT2AKDM4EALDH1A1LMNA
SCHEMBL17107198 0.82 TDP1 (0.68) ESR1ESR2TDP1KMT2AKDM4E
SCHEMBL1811235 0.82 TDP1 (0.68) TDP1KMT2AKDM4EALDH1A1MEN1
4-Hydroxyhydrocinnamic Acid Methyl Ester SCHEMBL95254 0.80 HDAC2 (0.53) ESR1ESR2TDP1KMT2AKDM4E
SCHEMBL21546065 0.80 TDP1 (0.66) TDP1KMT2AKDM4EALDH1A1MEN1
Hydrochloric Acid SCHEMBL28018100 0.80 TDP1 (0.66) TDP1KMT2AKDM4EALDH1A1MEN1
SCHEMBL4965775 0.79 APP (0.68) TDP1KDM4EALDH1A1CYP19A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109593068-A A kind of intermediate and preparation method thereof of ROR gamma inhibitors 广东东阳光药业有限公司 2019-04-09 CN disclosed
US-20070142472-A1 Process for producing optically active 3-(4-hydroxyphenyl)proprionic acids TAKASAGO INTERNATIONAL CORPORATION (JP) 2007-06-21 US disclosed
EP-1687250-A1 PROCESS FOR PRODUCING OPTICALLY ACTIVE 3-(4-HYDROXYPHENYL)PROPIONIC ACIDS Takasago International Corporation (JP) 2006-08-09 EP disclosed
WO-2005051882-A1 PROCESS FOR PRODUCING OPTICALLY ACTIVE 3-(4-HYDROXYPHENYL)PROPIONIC ACIDS TAKASAGO INTERNATIONAL CORPORATION (JP) 2005-06-09 WO disclosed
US-20030162799-A1 Carbocyclic oxo, carboxy amines such as 3-(4-(3,5-Dichloro-4-pyridylcarboxamido)phenyl)-2-(2-propylamino-3,4 -dioxocyclobut-1-enyl)amino)propanoic acid, used as integrin antagonists; antiinflammatory agents CELLTECH R&D LIMITED (GB) 2003-08-28 US disclosed
US-6518283-B1 To modify integrin function in such a way as to beneficially modulate cell adhesion CELLTECH R&D LIMITED (GB) 2003-02-11 US disclosed
EP-1181266-A1 SQUARIC ACID DERIVATIVES AS CELL ADHESION MOLECULES Celltech R&D Limited (GB) 2002-02-27 EP disclosed
WO-2000073260-A1 SQUARIC ACID DERIVATIVES AS CELL ADHESION MOLECULES CELLTECH R&D LIMITED (GB) 2000-12-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070142472-A1 Process for producing optically active 3-(4-hydroxyphenyl)proprionic acids ALDH1A2, ALDH1A3, GRHPR ESR1 2687/4885ESR2 3089/4885TDP1 3826/4885
US-20030162799-A1 Carbocyclic oxo, carboxy amines such as 3-(4-(3,5-Dichloro-4-pyridylcarboxamido)phenyl)-2-(2-propylamino-3,4 -dioxocyclobut-1-enyl)amino)propanoic acid, used as integrin antagonists; antiinflammatory agents ICAM1, VCAM1, CCR1 ESR1 3949/4885ESR2 2464/4885TDP1 3793/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.